

Self-Perceived Decline in Memory and Concentration 9 and 12 months post COVID-19 infection

1 **Carolina Ruivinho¹, Marta Moniz¹, Ana Rita Goes¹, Patrícia Soares^{1,2,3}, Andreia Leite^{1,3,*} and**
2 **LOCUS group**

3 ¹NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research
4 Center, CHRC, LA-REAL, CCAL, NOVA University Lisbon, Lisbon, Portugal

5 ² Centre for Vectors and Infectious Diseases Research, National Institute of Health Doutor Ricardo
6 Jorge, Águas de Moura, Portugal

7 ³ Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

8
9
10
11 *** Correspondence:**

12 Andreia Leite

13 andreia.leite@ensp.unl.pt

14
15 **Keywords: Cognitive decline, Concentration issues, COVID-19 infection, Long Covid, Post-**
16 **COVID condition, SARS-CoV-2, Memory loss.**

17
18
19 **Abstract**

20 **Introduction:** COVID-19 infection caused by SARS-CoV-2 has led to significant long-term health
21 challenges, including Long COVID or Post-COVID condition, that can include symptoms such as
22 cognitive decline, memory loss, and concentration issues. This study investigates the prevalence and
23 risk factors of post-COVID cognitive symptoms among individuals tested for COVID-19.

24 **Methods:** A cross-sectional study was conducted in Lisbon and Tagus Valley, targeting individuals
25 tested for COVID-19 in August 2022. Participants were selected from a random sample of 10,000
26 individuals. Data were collected via computer-assisted telephone interviews at 9 and 12 months post-
27 test, covering sociodemographic details, health behaviors, pre-existing conditions, and COVID-19
28 symptoms. The primary outcome was the presence of at least one cognitive symptom (memory loss
29 and/or concentration issues) at 9 and 12 months. Additionally, each symptom was assessed
30 individually, along with a composite outcome of both symptoms concurrently.

31 **Results:** At 9 months, memory loss was reported by 24.87% of COVID-19 positive cases versus
32 10.20% of negatives, and concentration issues by 15.45% of positives versus 7.45% of negatives. At
33 12 months, memory loss prevalence was 16.67% for positives and 9.45% for negatives, while
34 concentration issues were 9.82% for positives and 2.99% for negatives. Additionally, the prevalence
35 of at least one cognitive symptom was 28.24% in positive cases at 9 months compared to 12.16% in
36 negatives, and 17.81% versus 9.95% at 12 months. Female sex was significantly associated with a
37 higher prevalence of cognitive symptoms at both time points.

38 **Discussion:** These findings underscore the enduring cognitive impact of COVID-19, with significant
39 disparities in cognitive symptoms between COVID-19 positive and negative individuals observed at

40 both 9 and 12 months post-infection. The higher prevalence of memory loss and concentration issues
41 among COVID-19 positives suggests potential neurological sequelae linked to SARS-CoV-2 infection.
42 Notably, the association of female sex with increased cognitive symptom prevalence warrants further
43 investigation into gender-specific vulnerabilities or biological mechanisms underlying these
44 disparities. Addressing these persistent cognitive symptoms is crucial for long-term patient
45 management and underscores the need for targeted interventions and comprehensive post-COVID care
46 strategies to mitigate long-lasting health implications.

47

48 **1 Introduction**

49 The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
50 coronavirus 2 (SARS-CoV-2), has posed significant challenges globally, extending beyond acute
51 illness to encompass a spectrum of long-term sequelae (Soriano et al., 2022). While initially recognized
52 as primarily a respiratory illness, emerging evidence underscores its multiorgan impact, including
53 notable neurological and cognitive manifestations both during and after acute infection (Gonzalez-
54 Fernandez & Huang, 2010; Möller et al., 2023; Soriano et al., 2022). After recovering from COVID-
55 19, some individuals experience persistent symptoms, a condition commonly referred to as post-
56 COVID condition (PCC) or Long COVID. These symptoms, which may appear either newly or persist
57 from the initial illness, typically last for at least two months, cannot be explained by another diagnosis,
58 and include fatigue, breathing difficulties, and cognitive issues (Soriano et al., 2022). Prevalence has
59 been estimated to be between 10% to 70% (Al-Aly et al., 2022; Crook et al., 2021; Davis et al., 2023;
60 Fernández-de-Las-Peñas et al., 2022; Pérez-González et al., 2022; Sahanic et al., 2023; Wu et al., 2021;
61 Yaksi et al., 2022) of previously infected patients, depending on vaccination status, severity of initial
62 disease and several other factors. The impact of COVID-19 extends beyond physical health,
63 significantly affecting various sectors such as psychiatric hospitals and elder care institutions,
64 highlighting the need to address the unique challenges faced by underserved populations during the
65 pandemic. A recent study reported that, out of 19,573 patients hospitalized in psychiatric hospitals
66 across 17 studies from different regions of the world, a pooled mean of 11.9% were diagnosed with
67 COVID-19 (Maximiano-Barreto et al., 2024). Additionally, another review that focused on 48 articles
68 related to elder care institutions identified new risk factors that can inform healthcare services aimed
69 at protecting vulnerable residents in nursing homes (Yin et al., 2024).

70 In the realm of Long COVID research, cognitive symptoms, such as memory loss, concentration issues,
71 and brain fog, have gained prominence. A recent study comparing cognitive abilities across COVID-
72 19 patient groups found that those with persistent symptoms displayed deficits in working and
73 prospective memory tasks, such as remembering appointments and object recall. Additionally,
74 individuals with persistent COVID-19 symptoms reported more frequent everyday memory lapses
75 compared to controls (Espinár-Herranz et al., 2023). Among an array of studies, memory loss emerges
76 as a prevalent cognitive manifestation (11% to 34.5%) (Ahmed et al., 2022; Fernández-de-las-Peñas et
77 al., 2023; Garrigues et al., 2020; Keijsers et al., 2022; Merza et al., 2023; Pilotto et al., 2021; Søråas et
78 al., 2021), while concentration issues exhibit a lower prevalence (2.6% to 31%) and have received
79 comparatively less research attention (Fernández-de-las-Peñas et al., 2023; Keijsers et al., 2022; Søråas
80 et al., 2021). Moreover, hospitalized patients show a higher prevalence of cognitive post-COVID
81 complications, aligning with trends in other symptom categories (Garrigues et al., 2020; Keijsers et al.,
82 2022; Pérez-González et al., 2022). Regarding their trajectory, most studies indicate that these
83 cognitive symptoms decline over time following infection (Baseler et al., 2022; Fernández-de-las-Peñas

84 et al., 2023). Nonetheless, some studies suggest that these symptoms may worsen over time or even
85 emerge only after 12 months post-infection(Fernández-de-las-Peñas et al., 2023; Ling et al., 2024).

86 The neurotropic potential of COVID-19, along with associated structural brain alterations, respiratory
87 complications, and critical care interventions, can explain memory loss and cognitive issues(Douaud
88 et al., 2022; Taquet et al., 2023). This underscores the imperative for comprehensive approaches in
89 addressing post-infection cognitive sequelae. Despite the growing recognition of neuropsychological
90 symptoms in post-COVID patients, the predominant focus in research remains on physical
91 manifestations, particularly respiratory symptoms. While some studies are emerging to investigate the
92 prevalence of Long COVID cognitive complications, very few delve into their underlying risk factors.
93 Moreover, most existing knowledge focuses on hospitalized or mixed populations and lacks a
94 comparison group. From a public health perspective, representative samples of COVID-19 cases and
95 non-infected comparators allow to estimate the burden of these complications.

96 This study aims to address existing knowledge gaps by comparing the prevalence of memory and
97 concentration loss between individuals who tested positive and negative for COVID-19 at 9 and 12
98 months post-test. Additionally, we aim to investigate the factors influencing memory loss and
99 concentration issues at these time-points. Based on the existing literature, we hypothesize that
100 individuals who tested positive for COVID-19 will report higher prevalence rates of memory loss and
101 concentration issues compared to those who tested negative, and that factors such as age, sex, previous
102 infections, and education levels may significantly influence these cognitive outcomes.

103 **2 Materials and methods**

104 **2.1 Study design and data collection**

105 This cross-sectional study targeted individuals residing in Lisbon and Tagus Valley, encompassing
106 one-third of the country's population spread across urban and rural areas. Residents with positive and
107 negative SARS-CoV-2 test notifications from the National System of Epidemiological Surveillance
108 (SINAVE) in August 2022 were invited to participate. The General Directorate of Health (DGS)
109 provided the research team with participant information in two phases. On February 28, 2023, the data
110 owner initially provided contact information, including names and cellphone numbers, for a randomly
111 selected sample of 10,000 individuals who had undergone SARS-CoV-2 testing. From March 15, 2023,
112 to June 14, 2023, trained interviewers obtained verbal informed consent via telephone, providing
113 participants the opportunity to either accept or decline participation. Upon obtaining consent, we
114 received eligible individuals' birthdates and test results and applied the questionnaire through a 30-
115 minute computer-assisted telephone interview. Data collection occurred at two time-points: the first
116 approximately nine months after the SARS-CoV-2 test (between June 12 and August 8 of 2023) and
117 the second approximately twelve months after the SARS-CoV-2 test (between September 27 and
118 November 10 of 2023). Calls were scheduled for the most convenient times for the participants, with
119 a maximum of five call attempts at different hours. The questionnaire gathered sociodemographic data,
120 previous comorbidities, COVID-19 care levels (home-based, primary care, emergency department,
121 hospital admission, hospital admission in intensive care), lifestyle behaviors (e.g., alcohol intake,
122 smoking, physical exercise), and symptoms reported during testing and within the seven days before
123 each interview. Individuals were free not to answer any question, and in questions related to symptoms
124 and health conditions, there was also the option "I do not know."

125 **2.2 Study population and sample size**

126 We included individuals who underwent an SARS-CoV-2 test in August 2022, resided in Lisbon and
127 Tagus Valley region during the study period, were 18 years old or older, and consented to participate,
128 regardless of their nationality or immigration status. We excluded individuals who: i) did not have a
129 valid landline or mobile phone number registered; ii) were institutionalized (e.g. residential structures
130 for the elderly or prisons); iii) died between the date of the test and the call; iv) had language barriers
131 (languages not covered by the group of translators that were part of the team of investigators) or
132 deafness, as well as advanced states of mental illness or dementia; v) were Portuguese tourists or
133 emigrants on holidays in Portugal; and vi) tested positive for SARS-CoV-2 after August 2022 but
134 before completing the questionnaire, ensuring an equal time between the test and Long COVID
135 assessment for all participants. Further details on the data collection process and study population can
136 be found in the published study protocol(Dinis Teixeira et al., 2023).

137 **2.3 Variables**

138 The primary outcome of this study was the presence of at least one cognitive symptom (memory loss
139 and/or concentration issues) assessed at two distinct time-points: 9 and 12 months following the SARS-
140 CoV-2 test. Regarding the selection of the 9- and 12-month time points, these were based on previous
141 studies indicating that long-term cognitive symptoms can persist for a year or longer following
142 COVID-19 infection(Fernández-de-las-Peñas et al., 2023). Our goal was to describe potential
143 variations in the trajectory of cognitive symptoms, specifically memory and concentration problems,
144 over time. By assessing these symptoms at both 9 and 12 months post-infection, we aimed to identify
145 any changes in symptom prevalence or severity as recovery progressed beyond the acute phase of the
146 illness. Additionally, we assessed each symptom individually (memory loss and concentration issues)
147 as well as a composite outcome indicating the presence of both memory loss and concentration issues
148 concurrently at these specified time-points. Symptom data were self-reported using a
149 Yes/No/Unknown format in a questionnaire based on the International Severe Acute Respiratory and
150 Emerging Infection Consortium (ISARIC) and WHO COVID-19 Clinical Characterisation
151 Protocol(Sigfrid et al., 2021). Participants were asked about 'difficulty remembering' and 'confusion or
152 lack of concentration' experienced in the seven days prior to the interview. The 7-day recall period was
153 chosen to minimize recall bias and ensure that participants were reporting recent symptoms rather than
154 symptoms experienced in the distant past. Further details can be found in the supplementary materials
155 (S1B) of the published protocol(Dinis Teixeira et al., 2023). We further used information on
156 demographic characteristics: sex (male/female), age (in years), education level (medium, primary
157 education or lower education; secondary education; higher education), worker (yes/no); behavioral and
158 clinical characteristics: alcohol consumption (never/ 2 to 4 times a month or less/ twice a week or
159 more), physical exercise (defined as ≥ 30 minutes daily - yes/no), and pre-existing health conditions
160 (previous COVID-19 infection, previous psychiatric condition); and COVID-19 related factors:
161 number of symptoms at COVID-19 test, level of care needed (hospitalized/non-hospitalized), number
162 of COVID-19 vaccine doses administered at the time of the first interview. Working status was
163 assessed at each time-point, while the remaining data was only collected during the initial interview at
164 9 months.

165 **2.4 Statistical analysis**

166 Categorical data was summarised as frequencies and percentages, and continuous data were presented
167 as mean (minimum and maximum) and median, along with the corresponding interquartile range (IQR)
168 shown as the 25th and 75th percentiles. Prevalence estimates for SARS-CoV-2 positive and SARS-
169 CoV-2 negative participants were calculated for all four outcomes (memory loss, concentration issues,
170 at least one cognitive symptom and both cognitive symptoms concurrently) by dividing the number of

171 individuals reporting specific symptoms (such as concentration issues and memory loss) at 9 months
172 and 12 months post-testing by the total number of participants in each group, accompanied by a 95%
173 confidence interval (95%CI). A sensitivity analysis was performed for all four outcomes, excluding
174 participants over 60 years old due to the greater age-related cognitive decline in this group(Hedden &
175 Gabrieli, 2004). This analysis aimed to assess the variation in the prevalence of post-COVID cognitive
176 symptoms, eliminating the influence of age-related cognitive decline. We further investigated the
177 association between SARS-CoV-2 positivity and cognitive symptoms by calculating the difference in
178 proportions between positive and negative test groups at 9 and 12 months follow-up to investigate the
179 proportion of symptoms explained by Long COVID.

180 To explore the association between individuals' characteristics and the primary outcome (presence of
181 at least one cognitive symptom), we considered only the individuals with a positive SARS-CoV-2 test.
182 Sex, age, education level (as a proxy for income), alcohol intake, physical exercise, COVID-19
183 symptoms status, pre-existing health conditions (COVID-19, psychiatric condition), and the number
184 of COVID-19 vaccine doses were included as independent variables. These variables were selected in
185 accordance with the possible factors identified in the literature that could affect the onset of post-
186 COVID-19 cognitive symptoms(Ahmed et al., 2022; Al-Aly et al., 2021; Crook et al., 2021; Greißel et
187 al., 2024; Hüfner et al., 2022; Merza et al., 2023; Pilotto et al., 2021; Wang et al., 2021). Given that
188 odds ratios can be overestimated in the presence of frequent events, a robust Poisson regression was
189 employed. This method yields more reliable estimations than logistic regression when analyzing binary
190 outcomes from cross-sectional studies(Barros & Hirakata, 2003). Crude and adjusted prevalence ratios
191 (PR) were estimated, alongside respective 95%CI, adjusting for all the aforementioned variables.
192 Overall, missing values were implicitly handled by subsetting the data based on complete cases for
193 each variable included in the analysis. Data were analyzed using R version 4.3.2.

194 **3 Results**

195 From the individuals tested in August 2022, we had access to a random sample of 10,000. Due to
196 privacy concerns and our 9-month deadline, we contacted 6,642 people for the initial questionnaire,
197 with 1,229 consenting to participate. Among them, 120 dropped out, 226 were unreachable, and 65
198 were ineligible (due to COVID-19 reinfection between the date of the test and the questionnaire date).
199 Thus, a final sample of 818 participants was included in the 1st follow-up analysis. Within this group,
200 563 tested positive for SARS-CoV-2. After completing the first survey, 47 participants dropped out
201 and 70 were unreachable for the second interview. Additionally, 62 participants were excluded from
202 the analysis because they contracted COVID-19 between the first interview and the completion of the
203 second questionnaire. This resulted in a final sample of 639 participants included in the follow-up
204 analysis. Among them, 438 tested positive for SARS-CoV-2. Further details are provided in Figure 1.

205 A characterization of participants included at each time-point, considering sociodemographic,
206 behavioral, and clinical characteristics prior to the SARS-CoV-2 test is present at table 1. At 9-month
207 follow-up, those with positive tests tended to be younger (median 52 vs. 54 years old), female (58.3%
208 vs. 53.7%), possessed higher education levels (46.4% vs. 35.7%), and were employed (67.1% vs.
209 54.9%). Participants who practiced regular physical exercise (≥ 30 minutes daily) were more common
210 among negative cases (38.9% vs. 43.9%). Individuals testing positive tended to exhibit a higher
211 frequency of alcohol consumption and the majority of participants across both groups reported
212 consuming alcohol 2 to 4 times a month or less. Among the 639 participants who completed the 12-
213 month follow-up, those with positive tests similarly tended to be younger (median 53 vs. 55 years old),
214 more often female (58.5% vs. 50.8%), possessed higher education levels (46.6% vs. 37.8%), and were
215 employed (65.30% vs. 58.7%). Consistent with findings from the first time-point, participants who

216 practiced regular physical exercise were more common among negative cases (38.1% vs. 45.3%).
217 Alcohol consumption exhibited an identical distribution pattern to the first follow-up. Regarding pre-
218 existing medical conditions, prior COVID-19 infection and a history of psychiatric conditions were
219 more common among individuals in the positive group at both 9 (21.9% vs. 15.7%; 17.2% vs. 13.7%,
220 respectively) and 12 months (21.7% vs. 14.4%; 18.3% vs. 13.4%, respectively). On average,
221 participants from both follow-ups with a positive SARS-CoV-2 test reported the presence of six
222 symptoms at the time of the test, while participants with a negative test reported one symptom. The
223 proportion of hospitalised participants, among those who tested positive, was residual at both time-
224 points ($\approx 1\%$). Moreover, the results regarding vaccination status were consistent across all groups and
225 time-points, with each group having an average of three vaccines administered.

226 Our study analyzed the prevalence of each outcome among individuals tested for SARS-CoV-2, as
227 detailed in Figure 2 and Supplementary Table 1, and complemented this with a difference of proportion
228 analysis (Table 2). Memory loss showed a higher prevalence among individuals who tested positive
229 (prevalence [Pr]: 24.87, 95% confidence interval [CI]: 21.35; 28.65) compared to those who tested
230 negative (Pr: 10.20, 95%CI: 6.77; 14.58) at the 9-month follow-up, with a significant difference of
231 proportion between prevalences (14.81, 95% CI: 9.35; 20.27). Similarly, among participants in the
232 subsequent survey, memory loss was more prevalent in those with a positive test result (Pr: 16.67, 95%
233 CI: 13.30; 20.49) compared to those with a negative result (Pr: 9.45, 95% CI: 5.79; 14.37), with a
234 difference of proportions of 7.33 (95% CI: 1.61; 13.05). Concentration issues were also more prevalent
235 among participants with a positive test result, both at the 9-month follow-up (Pr: 15.45, 95% CI: 12.57;
236 18.71 vs. Pr: 7.45, 95% CI: 4.55; 11.39), with a difference of proportions of 8.08 (95% CI: 3.39; 12.79),
237 and at the 12-month follow-up (Pr: 9.82, 95%CI: 7.20; 13.00 vs. Pr: 2.99, 95%CI: 1.10; 6.38), with a
238 difference of proportions of 6.83 (95% CI: 2.82; 10.84). Examining the prevalence of both symptoms,
239 the presence of at least one cognitive symptom at 9 months was more prevalent in the positive test
240 group (Pr: 28.24, 95% CI: 24.56; 32.16) compared to the negative test group (Pr: 12.16, 95% CI: 8.41;
241 16.81), with a difference of proportions of 16.14 (95% CI: 10.36; 21.91). At the 12-month follow-up,
242 the prevalence was still higher in the positive test group (Pr: 17.81, 95% CI: 14.34; 21.72) compared
243 to the negative test group (Pr: 9.95, 95% CI: 6.18; 14.95), with a difference of proportions of 7.90 (95%
244 CI: 2.06; 13.74). Moreover, the prevalence of having both symptoms was higher in the positive group
245 at 9 months (Pr: 12.08, 95% CI: 9.50; 15.06 vs. Pr: 5.49, 95% CI: 3.03; 9.04), with a difference of
246 proportions of 6.61 (95% CI: 2.43; 10.79), and at the 12-month follow-up (Pr: 8.68, 95% CI: 6.21;
247 11.71 vs. Pr: 2.49, 95% CI: 0.81; 5.71), with a difference of proportions of 6.19 (95% CI: 2.42; 9.95).

248 Furthermore, to assess the potential impact of age-related cognitive decline on our findings, we
249 conducted a sensitivity analysis, excluding participants aged 60 years or older (see Supplementary
250 Table 2 for complete analysis). We found similar trends regarding each symptom individually. Notably,
251 the prevalence of having at least one cognitive symptom revealed a significantly higher prevalence in
252 those with a positive test at 12-month follow-up (Pr: 11.87; 95%CI: 9.00; 15.28 vs. Pr: 4.48; 95%CI:
253 2.07; 8.33), supported by a difference of proportions of 11.33 (95% CI: 4.18; 18.49). Regarding the
254 presence of both symptoms, a higher prevalence was still observed among the positive group at both
255 the 9-month (Pr: 7.28; 95% CI: 5.28; 9.75 vs. Pr: 2.75; 95% CI: 1.11; 5.57) and 12-month (Pr: 5.48;
256 95% CI: 3.54; 8.04 vs. Pr: 1.00; 95% CI: 0.12; 3.55) follow-ups. When estimating the difference in
257 proportions, we found that the disparity between the groups remained statistically significant for all
258 studied outcomes at both time-points (Supplementary Table 3).

259 The comparison of cognitive symptoms between age groups (under 60; 60 and over) at both time-
260 points is further depicted in Figure 3. Individuals aged 60 and over exhibit a higher prevalence of all
261 outcomes except concentration issues and at least one cognitive symptom at the 12-month follow-up.

262 Nevertheless, the overall distribution remains highly consistent across both age groups, with both
263 groups showing a decline in the prevalence of all outcomes over time.

264 We further analyzed the sociodemographic, behavioral, and clinical factors associated with having at
265 least one cognitive symptom in participants who tested positive for SARS-CoV-2 (Table 3). Our
266 adjusted results reveal a significant association between being female and post-COVID-19 cognitive
267 symptoms, evident both at 9 months (Adjusted Prevalence Ratio [aPR]: 2.02, 95% CI: 1.42; 2.87) and
268 12 months (aPR: 1.97, 95% CI: 1.19; 3.26). The distribution of key demographic and health variables,
269 including age, COVID-19 test results, education level, and previous COVID-19 infection status,
270 between males and females at both the 9- and 12-month follow-ups is provided in Supplementary Table
271 4. Additionally, while a history of psychiatric condition showed significance in unadjusted results at 9
272 months (aPR: 1.50, 95% CI: 1.11; 2.02), this association did not maintain significance following
273 adjustment. Analysis of the remaining variables (age, education level, alcohol intake, physical exercise,
274 prior COVID-19 infection, and COVID-19 vaccine doses) revealed no significant association with
275 post-COVID-19 cognitive symptoms.

276 **4 Discussion**

277 One of the key findings of this study is the higher prevalence of memory loss and concentration issues
278 among individuals who tested positive for SARS-CoV-2 compared to those who tested negative at both
279 9-month and 12-month follow-up. Furthermore, in participants who tested positive, we found that being
280 female was associated with a higher prevalence of Long COVID symptoms at both time-points.

281 Our results show that at 9 months memory loss and concentration issues had a prevalence rate of 24.9%
282 and 15.5%, respectively. At 12 months, prevalence rates decreased but were still more prevalent among
283 positive cases, with 16.7% of the participants reporting memory loss and 9.8% reporting concentration
284 issues. This finding aligns with previous research reporting a prevalence between 11.0% and 34.5%
285 for memory loss and 2.6% and 31.0% for concentration issues (Ahmed et al., 2022; Fernández-de-las-
286 Peñas et al., 2023; Garrigues et al., 2020; Keijsers et al., 2022; Merza et al., 2023; Pilotto et al., 2021;
287 Søråas et al., 2021). Differences in study designs, follow-up periods, collection procedures, and
288 populations, may explain the heterogeneous prevalence rates among studies. For instance, studies with
289 hospitalized patients often show higher prevalences of cognitive post-COVID complications, as these
290 symptoms seem to manifest more in patients with initially severe disease (Fernández-de-Las-Peñas et
291 al., 2022; Garrigues et al., 2020; Keijsers et al., 2022; Pérez-González et al., 2022).
292 Fernández-de-las-Peñas et al. (Fernández-de-Las-Peñas et al., 2022) showed that two years after SARS-
293 CoV-2 infection, memory loss was reported by 20.0% of hospitalized patients versus 15.9% of non-
294 hospitalized patients. However, these symptoms are not exclusive to severe cases and have also been
295 noted in patients with initially mild COVID-19 infection, emphasizing the importance of studies
296 focused on mild cases, such as ours, where less than 1.0% of participants required hospitalization.
297 Pilotto et al. (Pilotto et al., 2021) showed that among mild cases 33.3% reported memory and/or
298 concentration problems at 6-months follow-up. Similarly, in our study, among those testing positive,
299 the prevalence of having at least one cognitive symptom was 28.2% at the 9-month follow-up, dropping
300 to 17.8% at 12 months, with a difference of proportions of 16.14 and 7.90, respectively. Other studies
301 also showed a tendency for cognitive symptoms to decline over time following infection [17,18]. Baeler
302 et al. [18] implemented an online quiz to investigate working memory following COVID-19 infection.
303 Their study revealed a gradual increase in memory scores over a 17-month period post-COVID-19,
304 indicating a decrease in cognitive impairment over time. Another study indicated that out of the 14.9%
305 of patients reporting memory loss approximately 8 months post-infection, only 5.8% continued to
306 experience these symptoms at 12 months [17]. However, the same study revealed that approximately

307 6.0% of participants who did not exhibit memory loss at the initial assessment developed it 12 months
308 after infection. This highlights the importance of investigating post-COVID cognitive symptoms,
309 especially beyond the one-year mark following infection.

310 Moreover, most studies evaluating post-COVID cognitive symptoms overlook the impact of age-
311 related cognitive decline. This cognitive decline may start as early as in one's 20s and 30s(Salthouse,
312 2009). However, the pace of cognitive decline tends to accelerate, especially after the age of 60(Hedden
313 & Gabrieli, 2004). Despite evidence suggesting older individuals are more prone to memory
314 impairment as a post-COVID symptom, this remains debated among researchers(Baseler et al., 2022;
315 Merza et al., 2023). The sensitivity analysis excluding participants aged 60 years or older revealed that
316 among younger individuals with a positive SARS-CoV-2 test, our results showed similar trends, with
317 memory loss being more prevalent at the 9-month follow-up and concentration issues more prevalent
318 at both time points compared with those who tested negative for SARS-CoV-2. This analysis
319 demonstrated a reduced influence of age-related cognitive decline on our findings, highlighting the
320 consistency of our results. Moreover, although participants aged 60 or over showed a slightly higher
321 prevalence of all analyzed outcomes compared to their younger counterparts, the overall distribution
322 across age groups was very similar, with both groups showing a notable decline in all outcomes over
323 time. These findings indicate that while older adults may be more susceptible to certain cognitive
324 impairments, younger individuals were also impacted by these post-COVID complications. Future
325 research should continue to explore these age-related differences better to tailor post-COVID care and
326 support for diverse age groups.

327 Additionally, we analyzed individual factors associated with post-covid cognitive symptoms in
328 participants with a positive test result. Being female emerged as a significant risk factor for developing
329 post-covid cognitive symptoms, consistent with previous studies(Merza et al., 2023) highlighting
330 gender disparities in COVID-19 outcomes. While an interaction analysis between cognitive symptoms
331 and sex should be further explored, we believe that studies with larger cohorts would be better suited
332 to investigate this potential interaction. Additionally, older age, previous COVID-19 infection and not
333 being vaccinated have also been reported as risk factors(Merza et al., 2023; Pilotto et al., 2021) for
334 post-covid symptoms, however, no significant association was found in our results. Several factors
335 may contribute to this discrepancy, including variations in sample characteristics, such as the lack of
336 hospitalized participants and those with severe disease typically present in studies identifying these
337 risk factors(Al-Aly et al., 2021; Merza et al., 2023; Pilotto et al., 2021), as well as methodological
338 differences in study design, such as the reliance on self-reported symptoms which may limit the
339 accuracy of the reported symptom prevalence. Additionally, potential limitations in statistical power
340 and the influence of unaccounted confounding variables, such as comorbidities, may also affect the
341 results. Moreover, vaccination, the severity of acute infection, and symptom presentation (symptomatic
342 vs asymptomatic) may represent crucial risk factors identified in the literature(Al-Aly et al., 2021;
343 Jennings et al., 2023; Merza et al., 2023; Pilotto et al., 2021) that were not fully addressed in our study
344 due to data limitations, specifically the low number of participants with severe cases, the small number
345 of participants without vaccination, and insufficient representation of asymptomatic individuals. These
346 aspects underscore the need for further research with larger, more diverse cohorts to better understand
347 the complex interplay between risk factors and the development of post-COVID cognitive symptoms.

348 Furthermore, comorbidities might influence the development of post-COVID symptoms, yet specific
349 conditions associated with post-COVID memory loss and concentration issues remain poorly
350 understood. Multiple studies have demonstrated that pre-existing mental health conditions can affect
351 the severity of acute disease and elevate the risk of developing post-COVID symptoms(Greißel et al.,
352 2024; Hüfner et al., 2022; Wang et al., 2021). Therefore, we hypothesize that a prior history of

353 psychiatric conditions may increase the risk of post-COVID cognitive symptoms. While our findings
354 indicate an association between previous psychiatric conditions and post-COVID cognitive symptoms
355 at the 9-month follow-up, this relationship lost significance after adjusting for other variables.
356 However, it is worth noting that the proportion of participants with a history of these conditions may
357 be underestimated, as mental health disorders are often underdiagnosed due to stigma, limited access
358 to mental health services, and challenges in recognizing and accurately diagnosing symptoms, which
359 can be misunderstood, overlooked, or miscommunicated in clinical settings(Clement et al., 2015;
360 Corrigan et al., 2014; Kasper, 2006; Milton & Mullan, 2014). Thus, further research is essential to
361 explore the impact of pre-existing mental health conditions on post-COVID cognitive impairment. It
362 is crucial to acknowledge that our study possesses certain limitations that deserve careful attention. A
363 significant limitation of our study pertains to the control group. Although we used a control group
364 consisting of individuals with negative test results, reliance on negative test results does not guarantee
365 the absence of prior infections. At both time-points, around 15% and 21% of participants with negative
366 and positive SARS-CoV-2 tests, respectively, reported having a prior COVID-19 diagnosis.
367 Furthermore, we were only able to include a lower number of negative participants. This could
368 influence the outcomes and reduce the robustness of our findings. Moreover, the relatively small
369 sample size, especially notable during the second follow-up, may have failed to demonstrate some
370 associations between sociodemographic and clinical characteristics and post-COVID cognitive
371 symptoms. Additionally, given that our sample predominantly consists of adults and older adults, we
372 may have overlooked the prevalence distribution across other younger age groups. Furthermore, the
373 small number of hospitalized individuals in our sample poses a limitation on the incorporation of this
374 factor into our regression analysis. This is particularly significant as numerous studies have consistently
375 highlighted acute disease severity as a key risk factor contributing to the development of cognitive
376 symptoms subsequent to COVID-19 infection(Al-Aly et al., 2021; Merza et al., 2023; Pilotto et al.,
377 2021). However, even though we may lose some diversity regarding specific variables like
378 hospitalization or severity status, the use of a community-based sample in our study offers significant
379 advantages. Unlike clinical samples, which may be biased toward individuals seeking treatment,
380 community-based samples include individuals regardless of their health-seeking behavior, providing a
381 more representative and comprehensive picture of the population.

382 Considering the methodology used, most studies investigating post-COVID cognitive symptoms use
383 specific cognitive and memory assessment tools and tests that target various memory and cognitive
384 functions, complicating direct comparisons across studies. Furthermore, different terminologies, such
385 as "brain fog" and "cognitive impairment," encompass a range of symptoms that vary across studies,
386 leading to divergent interpretations, particularly with self-reported symptoms. In our study, we applied
387 a WHO-approved questionnaire (ISARIC) and participants were queried about symptoms experienced
388 in the preceding 7 days, which were absent before their SARS-CoV-2 test. However, it is crucial to
389 recognize that reported symptoms might also relate to conditions other than COVID-19, such as flu-
390 like symptoms that could emerge following the test, whether diagnosed or undiagnosed. Symptoms
391 were self-reported, relying on participants' comprehension, recollection, understanding of symptom
392 definitions, and personal assessment. To enhance clarity, we used plain language and avoided medical
393 terminology. Another constraint was our inability to thoroughly analyze the vaccination variable while
394 considering the vaccination dates, as we originally intended. This was due to data limitations and a
395 significant amount of missing information regarding the timing of COVID-19 vaccination (whether
396 administered post or prior infection), which is known to be a factor associated with Long COVID
397 symptoms, including cognitive symptoms(Byambasuren et al., 2023; Jennings et al., 2023). Still
398 considering the methodology used, we assessed symptoms at 9 and 12 months post-SARS-CoV-2 test.
399 These intervals are particularly noteworthy in light of emerging research suggesting that cognitive
400 symptoms might only surface as late as one year after infection(Fernández-de-las-Peñas et al., 2023).

401 Our study significantly enhances the understanding of post-COVID cognitive symptoms in Portugal
402 and addresses a crucial gap by comparing the prevalence of memory loss and concentration issues,
403 both individually and in their co-presence, among individuals who tested positive and negative for
404 SARS-CoV-2. Additionally, we tested SARS-CoV-2-negative individuals in the same month as the
405 positive group, minimizing time disparities between the two cohorts, unlike other studies that might
406 use different infections or individuals with no history of COVID-19 infection as the control group.
407 Furthermore, many studies investigating cognitive symptoms neglect the impact of age-related
408 cognitive decline. Our sensitivity analysis bridged this gap, allowing us to examine the prevalence of
409 post-COVID cognitive symptoms in a younger sample. This enhanced the robustness of our results and
410 revealed that younger people are also significantly affected by these post-COVID complications. As
411 such, their inclusion in future research and incorporation into public health strategies is crucial.

412 In summary, our analysis aimed to assess the prevalence of memory loss and concentration issues
413 between participants who tested positive and negative for SARS-CoV-2 and the factors associated with
414 post-COVID cognitive symptoms within SARS-CoV-2 positive test participants. Despite challenges
415 due to sample size, our results offer valuable insights. In a predominantly non-hospitalised population,
416 we found a higher prevalence of cognitive symptoms in patients with positive SARS-CoV-2 test,
417 peaking at 9 months post-infection and declining thereafter. Moreover, we show that these symptoms,
418 often overlooked and attributed to age-related conditions, are not exclusive to older populations,
419 underscoring the need for broader consideration. This evidence is crucial for clinicians, who should be
420 aware that these symptoms can occur in individuals with non-severe COVID-19 and may pose a
421 significant burden in everyday life.

422

423 **5 Conflict of Interest**

424 The authors declare that the research was conducted in the absence of any commercial or financial
425 relationships that could be construed as a potential conflict of interest.

426 **6 Author Contributions**

427 CR, MM, PS, AL contributed to the design of this study. CR, MM, and AL contributed to data
428 collection. Data preparation and statistical analysis were performed by CR with oversight from MM,
429 AL and PS. The first draft of the manuscript was produced by CR with feedback from all other authors.
430 All authors reviewed, edited, and approved the final version.

431 **7 Funding**

432 This study was sponsored by Pfizer (grant code #68639655; URL: <https://www.pfizer.pt/>). The funders
433 did not have a role in study design, data collection and analysis, decision to publish or preparation of
434 the manuscript.

435 **8 Acknowledgments**

436 The authors thank Direção-Geral da Saúde and Serviços Partilhados Ministério da Saúde for data
437 sharing and Pfizer for funding. We also thank all the participants for their valuable time and to the
438 interviewers for their perseverance, which was essential to collect these data.

439 **9 Ethics approval**

440 This study involved human participants and was approved by the Ethics Committee for Health of the
441 Regional Health Administration of Lisbon and Tagus Valley (2151/CES/2022) and the Data Protection
442 Officer of the General Directorate of Health. Verbal informed consent was obtained from the
443 participants prior to the questionnaire.

444 **12 LOCUS group**

445 André Peralta Santos, Andreia Costa, Andreia Vilas-Boas, António Carlos da Silva, Gabriel Atanásio,
446 Inês Simões, Joana Paixão, João V. Cordeiro, João Victor Rocha, Lelita Santos, Luísa Eça Guimarães,
447 Maria da Luz Brazão, Maria João Lobão, Mário Santos, Marta Sofia Fonseca, Patrícia Barbosa, Sofia
448 Nóbrega, Sónia Dias and Víctor Ramos.

449 **13 References**

- 450 Ahmed, M., Roy, S., Iktidar, M. A., Chowdhury, S., Akter, S., Islam, A. M. K., & Hawlader, M. D.
451 H. (2022). Post-COVID-19 Memory Complaints: Prevalence and Associated Factors.
452 *Neurologia (Barcelona, Spain)*. <https://doi.org/10.1016/J.NRL.2022.03.007>
- 453 Al-Aly, Z., Bowe, B., & Xie, Y. (2022). Long COVID after breakthrough SARS-CoV-2 infection.
454 *Nature Medicine*, 28(7), 1461–1467. <https://doi.org/10.1038/S41591-022-01840-0>
- 455 Al-Aly, Z., Xie, Y., & Bowe, B. (2021). High-dimensional characterization of post-acute sequelae of
456 COVID-19. *Nature*, 594(7862), 259–264. <https://doi.org/10.1038/S41586-021-03553-9>
- 457 Barros, A. J. D., & Hirakata, V. N. (2003). Alternatives for logistic regression in cross-sectional
458 studies: an empirical comparison of models that directly estimate the prevalence ratio. *BMC*
459 *Medical Research Methodology*, 3, 1–13. <https://doi.org/10.1186/1471-2288-3-21>
- 460 Baseler, H. A., Aksoy, M., Salawu, A., Green, A., & Asghar, A. U. R. (2022). The negative impact of
461 COVID-19 on working memory revealed using a rapid online quiz. *PLOS ONE*, 17(11).
462 <https://doi.org/10.1371/JOURNAL.PONE.0269353>
- 463 Byambasuren, O., Stehlik, P., Clark, J., Alcorn, K., & Glasziou, P. (2023). Effect of covid-19
464 vaccination on long covid: systematic review. *BMJ Medicine*, 2(1), e000385.
465 <https://doi.org/10.1136/BMJMED-2022-000385>
- 466 Clement, S., Schauman, O., Graham, T., Maggioni, F., Evans-Lacko, S., Bezborodovs, N., Morgan,
467 C., Rüsçh, N., Brown, J. S. L., & Thornicroft, G. (2015). What is the impact of mental health-
468 related stigma on help-seeking? A systematic review of quantitative and qualitative studies.
469 *Psychological Medicine*, 45(1), 11–27. <https://doi.org/10.1017/S0033291714000129>
- 470 Corrigan, P. W., Druss, B. G., & Perlick, D. A. (2014). The Impact of Mental Illness Stigma on
471 Seeking and Participating in Mental Health Care. *Psychological Science in the Public Interest* :
472 *A Journal of the American Psychological Society*, 15(2), 37–70.
473 <https://doi.org/10.1177/1529100614531398>
- 474 Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covid—mechanisms, risk
475 factors, and management. *BMJ*, 374. <https://doi.org/10.1136/BMJ.N1648>

- 476 Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023). Long COVID: major findings,
477 mechanisms and recommendations. *Nature Reviews. Microbiology*, 21(3), 133–146.
478 <https://doi.org/10.1038/S41579-022-00846-2>
- 479 Dinis Teixeira, J. P., Santos, M. J. D. S., Soares, P., de Azevedo, L., Barbosa, P., Boas, A. V.,
480 Cordeiro, J. V., Dias, S., Fonseca, M., Goes, A. R., Lobão, M. J., Moniz, M., Nóbrega, S.,
481 Peralta-Santos, A., Ramos, V., Rocha, J. V., da Silva, A. C., da Luz Brazão, M., Leite, A., &
482 Nunes, C. (2023). LOCUS (LONG Covid-Understanding Symptoms, events and use of services
483 in Portugal): A three-component study protocol. *PloS One*, 18(4).
484 <https://doi.org/10.1371/JOURNAL.PONE.0285051>
- 485 Douaud, G., Lee, S., Alfaro-Almagro, F., Arthofer, C., Wang, C., McCarthy, P., Lange, F.,
486 Andersson, J. L. R., Griffanti, L., Duff, E., Jbabdi, S., Taschler, B., Keating, P., Winkler, A. M.,
487 Collins, R., Matthews, P. M., Allen, N., Miller, K. L., Nichols, T. E., & Smith, S. M. (2022).
488 SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*, 604(7907),
489 697–707. <https://doi.org/10.1038/S41586-022-04569-5>
- 490 Espinar-Herranz, K., Delgado-Lima, A. H., Villatoro, B. S., Garaboa, E. M., Gómez, V. S., Vides, L.
491 G., Bouhaben, J., & Delgado-Losada, M. L. (2023). Memory, Emotion, and Quality of Life in
492 Patients with Long COVID-19. *Brain Sciences*, 13(12).
493 <https://doi.org/10.3390/BRAINSKI13121670>
- 494 Fernández-de-las-Peñas, C., Cancela-Cilleruelo, I., Rodríguez-Jiménez, J., Arias-Navalón, J. A.,
495 Martín-Guerrero, J. D., Pellicer-Valero, O. J., Arendt-Nielsen, L., & Cigarán-Méndez, M.
496 (2023). Trajectory of post-COVID brain fog, memory loss, and concentration loss in previously
497 hospitalized COVID-19 survivors: the LONG-COVID-EXP multicenter study. *Frontiers in*
498 *Human Neuroscience*, 17. <https://doi.org/10.3389/FNHUM.2023.1259660>
- 499 Fernández-de-Las-Peñas, C., Rodríguez-Jiménez, J., Cancela-Cilleruelo, I., Guerrero-Peral, A.,
500 Martín-Guerrero, J. D., García-Azorín, D., Cornejo-Mazzuchelli, A., Hernández-Barrera, V., &
501 Pellicer-Valero, O. J. (2022). Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection
502 Among Hospitalized vs Nonhospitalized Patients. *JAMA Network Open*, 5(11), e2242106.
503 <https://doi.org/10.1001/JAMANETWORKOPEN.2022.42106>
- 504 Garrigues, E., Janvier, P., Kherabi, Y., Le Bot, A., Hamon, A., Gouze, H., Doucet, L., Berkani, S.,
505 Oliosi, E., Mallart, E., Corre, F., Zarrouk, V., Moyer, J. D., Galy, A., Honsel, V., Fantin, B., &
506 Nguyen, Y. (2020). Post-discharge persistent symptoms and health-related quality of life after
507 hospitalization for COVID-19. *The Journal of Infection*, 81(6), e4–e6.
508 <https://doi.org/10.1016/J.JINF.2020.08.029>
- 509 Gonzalez-Fernandez, E., & Huang, J. (1910). Cognitive Aspects of COVID-19. *Current Neurology*
510 *and Neuroscience Reports*, 23, 531–538. <https://doi.org/10.1007/s11910-023-01286-y>
- 511 Greißel, A., Schneider, A., Donnachie, E., Gerlach, R., Tauscher, M., & Hapfelmeier, A. (2024).
512 Impact of pre-existing mental health diagnoses on development of post-COVID and related
513 symptoms: a claims data-based cohort study. *Scientific Reports 2024 14:1*, 14(1), 1–12.
514 <https://doi.org/10.1038/s41598-024-52656-6>
- 515 Hedden, T., & Gabrieli, J. D. E. (2004). Insights into the ageing mind: a view from cognitive
516 neuroscience. *Nature Reviews. Neuroscience*, 5(2), 87–96. <https://doi.org/10.1038/NRN1323>

- 517 Hüfner, K., Tymoszuk, P., Ausserhofer, D., Sahanic, S., Pizzini, A., Rass, V., Galffy, M., Böhm, A.,
518 Kurz, K., Sonnweber, T., Tancevski, I., Kiechl, S., Huber, A., Plagg, B., Wiedermann, C. J.,
519 Bellmann-Weiler, R., Bachler, H., Weiss, G., Piccoliori, G., ... Sperner-Unterweger, B. (2022).
520 Who Is at Risk of Poor Mental Health Following Coronavirus Disease-19 Outpatient
521 Management? *Frontiers in Medicine*, 9. <https://doi.org/10.3389/FMED.2022.792881>
- 522 Jennings, S., Corrin, T., & Waddell, L. (2023). A systematic review of the evidence on the
523 associations and safety of COVID-19 vaccination and post COVID-19 condition. *Epidemiology
524 and Infection*, 151. <https://doi.org/10.1017/S0950268823001279>
- 525 Kasper, S. (2006). Anxiety disorders: under-diagnosed and insufficiently treated. *International
526 Journal of Psychiatry in Clinical Practice*, 10(SUPPL. 1), 3–9.
527 <https://doi.org/10.1080/13651500600552297>
- 528 Keijsers, K., Broeders, M., Baptista Lopes, V., Klinkert, A., van Baar, J., Nahar-van Venrooij, L., &
529 Kerckhoffs, A. (2022). Memory impairment and concentration problems in COVID-19
530 survivors 8 weeks after non-ICU hospitalization: A retrospective cohort study. *Journal of
531 Medical Virology*, 94(9), 4512–4517. <https://doi.org/10.1002/JMV.27831>
- 532 Ling, D. Q., Gibney, G., James, F., Holmes, N. E., & Chua, K. Y. L. (2024). Post-COVID-19
533 condition symptoms 12 and 24 months after COVID-19 during the first month of the pandemic
534 in Melbourne: a cohort study. *The Medical Journal of Australia*, 220(6), 336–338.
535 <https://doi.org/10.5694/MJA2.52260>
- 536 Maximiano-Barreto, M. A., Alqueja Azorli, L., Mendes de Paula Pessoa, R., Ferreira, A. A., Ramos
537 Rezende, A. C., Moretti Luchesi, B., Inouye, K., & Chagas, M. H. N. (2024). COVID-19
538 Frequency in Hospitalized Psychiatric Patients: A Systematic Review. *Psychiatry*.
539 <https://doi.org/10.1080/00332747.2024.2379750>
- 540 Merza, M. A., Almufty, H. B., Younis, H. A., Rasool, S. O., & Mohammed, S. A. (2023). Memory
541 impairment among recovered COVID-19 patients: The prevalence and risk factors, a
542 retrospective cohort study. *Journal of Medical Virology*, 95(2).
543 <https://doi.org/10.1002/JMV.28459>
- 544 Milton, A. C., & Mullan, B. A. (2014). Communication of a mental health diagnosis: a systematic
545 synthesis and narrative review. *Journal of Mental Health*, 23(5), 261–270.
546 <https://doi.org/10.3109/09638237.2014.951474>
- 547 Möller, M., Borg, K., Janson, C., Lerm, M., Normark, J., & Niward, K. (2023). Cognitive
548 dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation.
549 *Journal of Internal Medicine*, 294(5), 563–581. <https://doi.org/10.1111/JOIM.13720>
- 550 Pérez-González, A., Araújo-Ameijeiras, A., Fernández-Villar, A., Crespo, M., Poveda, E., Cabrera, J.
551 J., del Campo, V., de Araujo, B. G., Gómez, C., Leiro, V., Longueira, M. R., López-Domínguez,
552 A., Ramón Lorenzo, J., Marcos, M., Teresa Pérez, M., Patiño, L., Pérez, S., Pérez-Fernández, S.,
553 Ramos, C., ... Viéitez, I. (2022). Long COVID in hospitalized and non-hospitalized patients in a
554 large cohort in Northwest Spain, a prospective cohort study. *Scientific Reports*, 12(1).
555 <https://doi.org/10.1038/S41598-022-07414-X>

- 556 Pilotto, A., Cristillo, V., Cotti Piccinelli, S., Zoppi, N., Bonzi, G., Sattin, D., Schiavolin, S., Raggi,
557 A., Canale, A., Gipponi, S., Libri, I., Frigerio, M., Bezzi, M., Leonardi, M., & Padovani, A.
558 (2021). Long-term neurological manifestations of COVID-19: prevalence and predictive factors.
559 *Neurological Sciences*, 42(12), 4903. <https://doi.org/10.1007/S10072-021-05586-4>
- 560 Sahanic, S., Tymoszuk, P., Luger, A. K., Hüfner, K., Boehm, A., Schwabl, A. P. C., Koppelstätter,
561 S., Kurz, K., Asshoff, M., Mosheimer-Feistritz, B., Coen, M., Pfeifer, B., Rass, V., Egger, A.,
562 Hörmann, G., Sperner-Unterweger, B., Helbok, R., Wöll, E., Weiss, G., ... Löffler-Ragg, J.
563 (2023). COVID-19 and its continuing burden after 12 months: a longitudinal observational
564 prospective multicentre trial. *ERJ Open Research*, 9(2).
565 <https://doi.org/10.1183/23120541.00317-2022>
- 566 Salthouse, T. A. (2009). When does age-related cognitive decline begin? *Neurobiology of Aging*,
567 30(4), 507–514. <https://doi.org/10.1016/J.NEUROBIOLAGING.2008.09.023>
- 568 Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J., Bozza, F., Palmieri, C.,
569 Munblit, D., Holter, J. C., Kildal, A. B., Reyes, L. F., Russell, C. D., Ho, A., Turtle, L., Drake,
570 T. M., Beltrame, A., Hann, K., Bangura, I. R., ... Scott, J. T. (2021). What is the recovery rate
571 and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global
572 longitudinal observational study protocol. *BMJ Open*, 11(3), e043887.
573 <https://doi.org/10.1136/BMJOPEN-2020-043887>
- 574 Søråas, A., Bø, R., Kalleberg, K. T., Støer, N. C., Ellingjord-Dale, M., & Landrø, N. I. (2021). Self-
575 reported Memory Problems 8 Months After COVID-19 Infection. *JAMA Network Open*, 4(7).
576 <https://doi.org/10.1001/JAMANETWORKOPEN.2021.18717>
- 577 Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., & Diaz, J. V. (2022). A clinical case definition
578 of post-COVID-19 condition by a Delphi consensus. *The Lancet. Infectious Diseases*, 22(4),
579 e102–e107. [https://doi.org/10.1016/S1473-3099\(21\)00703-9](https://doi.org/10.1016/S1473-3099(21)00703-9)
- 580 Taquet, M., Skorniewska, Z., Zetterberg, H., Geddes, J. R., Mummery, C. J., Chalmers, J. D., Ho, L.
581 P., Horsley, A., Marks, M., Poinasamy, K., Raman, B., Leavy, O. C., Richardson, M., Elneima,
582 O., McAuley, H. J. C., Shikotra, A., Singapuri, A., Sereno, M., Saunders, R. M., ... Koychev, I.
583 (2023). Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing
584 nervous system injury. *Brain Communications*, 6(1).
585 <https://doi.org/10.1093/BRAINCOMMS/FCAD357>
- 586 Wang, Q. Q., Xu, R., & Volkow, N. D. (2021). Increased risk of COVID-19 infection and mortality
587 in people with mental disorders: analysis from electronic health records in the United States.
588 *World Psychiatry : Official Journal of the World Psychiatric Association (WPA)*, 20(1), 124–
589 130. <https://doi.org/10.1002/WPS.20806>
- 590 Wu, X., Liu, X., Zhou, Y., Yu, H., Li, R., Zhan, Q., Ni, F., Fang, S., Lu, Y., Ding, X., Liu, H.,
591 Ewing, R. M., Jones, M. G., Hu, Y., Nie, H., & Wang, Y. (2021). 3-month, 6-month, 9-month,
592 and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a
593 prospective study. *The Lancet. Respiratory Medicine*, 9(7), 747–754.
594 [https://doi.org/10.1016/S2213-2600\(21\)00174-0](https://doi.org/10.1016/S2213-2600(21)00174-0)

595 Yaksi, N., Teker, A. G., & Imre, A. (2022). Long COVID in Hospitalized COVID-19 Patients: A
 596 Retrospective Cohort Study. *Iranian Journal of Public Health*, 51(1), 88.
 597 <https://doi.org/10.18502/IJPH.V51I1.8297>

598 Yin, C., Mpofu, E., Brock, K., & Ingman, S. (2024). Nursing Home Residents' COVID-19 Infections
 599 in the United States: A Systematic Review of Personal and Contextual Factors. *Gerontology and*
 600 *Geriatric Medicine*, 10.
 601 [https://doi.org/10.1177/23337214241229824/ASSET/IMAGES/LARGE/10.1177_23337214241](https://doi.org/10.1177/23337214241229824/ASSET/IMAGES/LARGE/10.1177_23337214241229824-FIG3.JPEG)
 602 [229824-FIG3.JPEG](https://doi.org/10.1177/23337214241229824/ASSET/IMAGES/LARGE/10.1177_23337214241229824-FIG3.JPEG)

603

604 **Figure 1.** Flowchart of study participants.

605 **Figure 2.** Prevalence of cognitive symptoms 9 and 12 months after SARS-CoV-2 test by test result.

606 **Figure 3.** Prevalence of cognitive symptoms among positive cases 9 and 12 months after SARS-CoV-2
 607 test by age group

608

609 **Table 1.** Characterisation of the participants sociodemographic and clinical characteristics and
 610 vaccination status before the SARS-CoV-2 test.

Variable	9-months follow-up N= 818		12-months follow-up N= 639	
	COVID-19 test result			
	Negative, N(%)	Positive, N(%)	Negative, N(%)	Positive, N(%)
	255 (31.2%)	563 (68.8%)	201 (31.5%)	438 (68.5%)
Age				
Mean (SD)	54 (18, 89)	52 (18, 92)	55 (18, 89)	53 (18, 92)
Median (IQR)	54 (43, 68)	52 (41, 64)	55 (45, 68)	53 (42, 66)
Sex				
Female	137 (53.73%)	328 (58.26%)	102 (50.75%)	256 (58.45%)
Male	117 (45.88%)	229 (40.67%)	98 (48.76%)	176 (40.18%)
Missing	1 (0.39%)	6 (1.07%)	1 (0.50%)	6 (1.37%)
Education level				
Medium, primary education or lower education	90 (35.29%)	141 (25.04%)	70 (34.83%)	111 (25.34%)
Secondary education	74 (29.02%)	159 (28.24%)	55 (27.36%)	121 (27.63%)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Higher education	91 (35.69%)	261 (46.36%)	76 (37.81%)	204 (46.58%)
Missing	0 (0.00%)	2 (0.36%)	0 (0.00%)	2 (0.46%)
Worker				
No	115 (45.10%)	184 (32.68%)	82 (40.80%)	151 (34.47%)
Yes	140 (54.90%)	378 (67.14%)	118 (58.71%)	286 (65.30%)
Missing	0 (0.00%)	1 (0.18%)	1 (0.50%)	1 (0.23%)
Alcohol consumption				
Never	93 (36.47%)	157 (27.89%)	66 (32.84%)	127 (29.00%)
2 to 4 times a month or less	105 (41.18%)	262 (46.54%)	87 (43.28%)	198 (45.21%)
2 times a week or more	57 (22.35%)	144 (25.58%)	48 (23.88%)	113 (25.80%)
Physical exercise (≥30 minutes daily)				
No	143 (56.08%)	343 (60.92%)	110 (54.73%)	270 (61.64%)
Yes	112 (43.92%)	219 (38.90%)	91 (45.27%)	167 (38.13%)
Missing	0 (0.00%)	1 (0.18%)	0 (0.00%)	1 (0.23%)
Previous COVID-19 infection				
No	214 (83.92%)	431 (76.55%)	172 (85.57%)	334 (76.26%)
Yes	40 (15.69%)	123 (21.85%)	29 (14.43%)	95 (21.69%)
Unknown	1 (0.39%)	7 (1.24%)	0 (0.00%)	7 (1.60%)
Missing	0 (0.00%)	2 (0.36%)	0 (0.00%)	2 (0.46%)
Previous psychiatric condition				
No	220 (86.27%)	463 (82.24%)	174 (86.57%)	355 (81.05%)
Yes	35 (13.73%)	97 (17.23%)	27 (13.43%)	80 (18.26%)
Missing	0 (0.00%)	3 (0.53%)	0 (0.00%)	3 (0.68%)
N° of symptoms experienced in the 7 days before the SARS-CoV-2 test				
Mean (SD)	1.33 (0.00, 12.00)	5.61 (0.00, 16.00)	1.27 (0.00, 12.00)	5.66 (0.00, 16.00)

Median (IQR)	0.00 (0.00, 1.00)	5.00 (3.00, 8.00)	0.00 (0.00, 1.00)	5.50 (3.00, 8.00)
Level of care needed				
Hospitalised	NA	3 (0.53%)	NA	2 (0.46%)
Non-hospitalised	NA	554 (98.40%)	NA	431 (98.40%)
Missing	NA	6 (1.07%)	NA	5 (1.14%)
N° of COVID-19 vaccine doses				
Mean (SD)	3.00 (0.00, 5.00)	2.99 (0.00, 5.00)	3.07 (0.00, 5.00)	3.01 (0.00, 5.00)
Median (IQR)	3.00 (3.00, 4.00)	3.00 (2.75, 4.00)	3.00 (3.00, 4.00)	3.00 (3.00, 4.00)
Missing	1 (0.39%)	3 (0.53%)	1 (0.50%)	3 (0.68%)

611 Notes: NA – Non-applicable.

612

613

614 **Table 2.** Difference of proportions analysis for cognitive symptoms at 9-month and 12-month follow-
615 ups.

	Frequency, N(%)		Difference of proportions	CI95%	p-value
	Negative	Positive			
9-months follow-up	N = 255	N = 563			
Memory Loss	26 (10.20%)	140 (24.87%)	14.81%	[9.35, 20.27]	<0.001
Concentration Issues	19 (7.45%)	87 (15.45%)	8.08%	[3.39, 12.79]	0.00221
At least one cognitive symptom	31 (12.16%)	159 (28.24%)	16.14%	[10.36, 21.91]	<0.001
Both cognitive symptoms	14 (5.49%)	68 (12.08%)	6.61%	[2.43, 10.79]	0.00544
12-months follow-up	N = 201	N = 438			
Memory Loss	19 (9.45%)	73 (16.67%)	7.33%	[1.61, 13.05]	0.0203
Concentration Issues	6 (2.99%)	43 (9.82%)	6.83%	[2.82, 10.84]	0.00432
At least one cognitive symptom	20 (9.95%)	78 (17.81%)	7.90%	[2.06, 13.74]	0.0142

Both cognitive symptoms 5 (2.49%) 38 (8.68%) 6.19% [2.4, 9.95] **0.00634**

616 Notes: 95%CI: 95% confidence interval; Bold refers to statistically significant values (p<0.05).

617

618

619 **Table 3.** Factors associated with the prevalence of post-COVID cognitive symptoms.

Variables	9-months follow-up (N = 546)				12-months follow-up (N = 422)			
	Crude		Adjusted		Crude		Adjusted	
	PR	95%CI	PR	95%CI	PR	95%CI	PR	95%CI
Sex								
Male	Ref.							
Female	1.95	[1.42, 2.67]	2.02	[1.42, 2.87]	1.62	[1.03, 2.54]	1.97	[1.19, 3.26]
Age								
Under 60	Ref.							
60 and over	1.1	[0.83, 1.45]	1.23	[0.89, 1.17]	0.8	[0.51, 1.24]	0.95	[0.58, 1.57]
Education level								
Higher education	Ref.							
Medium, primary education or lower education	0.94	[0.67, 1.33]	0.85	[0.57, 1.26]	0.61	[0.34, 1.09]	0.59	[0.31, 1.12]
Secondary education	1.04	[0.76, 1.43]	1.01	[0.73, 1.38]	0.96	[0.61, 1.53]	0.94	[0.58, 1.53]

Alcohol intake								
Never	Ref.							
2 to 4 times a month or less	1.13	[0.81, 1.57]	1.21	[0.87, 1.69]	0.86	[0.52, 1.43]	0.87	[0.51, 1.45]
Twice a week or more	1.05	[0.71, 1.53]	1.38	[0.92, 2.06]	1.24	[0.74, 2.10]	1.62	[0.90, 2.91]
Physical exercise								
Yes	Ref.							
No	1.24	[0.93, 1.65]	1.18	[0.88, 1.58]	0.98	[0.64, 1.49]	0.94	[0.61, 1.47]
Previous COVID-19 infection								
No	Ref.							
Yes	1.14	[0.84, 1.56]	1.03	[0.74, 1.43]	1.28	[0.81, 2.02]	1.18	[0.72, 1.93]
Psychiatric condition								
No	Ref.							
Yes	1.50	[1.11, 2.02]	1.23	[0.90, 1.68]	1.08	[0.65, 1.81]	0.84	[0.49, 1.44]
COVID-19 vaccine doses	0.99	[0.86, 1.15]	0.97	[0.82, 1.14]	0.85	[0.70, 1.03]	0.85	[0.68, 1.07]

620 Notes: PR: Prevalence ratio; 95%CI: 95% confidence interval; physical exercise was defined as ≥ 30 minutes daily; Bold
621 refers to statistically significant values.

622





Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.19.24319396>; this version posted December 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1




Figure 3